This morning, Sanofi delivered strong financial results for the third quarter with sales up 6.3% at CER to €9.4 billion, positioning us firmly in a new growth phase. Specialty Care, Vaccines and Consumer Healthcare (CHC) led the charge with key support from Emerging Markets.
Our goal to reshape the portfolio paid dividends with Specialty Care delivering a 36.1% increase, driven largely by our new global Rare Blood Disorder franchise and our new Immunology franchise, whose Dupixent sales increased to €225 million, mainly in the U.S. but new launches have expanded its reach to 13 countries.
Vaccines delivered 8.2% in sales growth, largely due to the resolution of the supply problem of Pentaxim® in China, with further growth expected for the GBU in the second half of 2018.
Our CHC business posted 4.1% growth and given our broad geographic footprint and leadership position, is keeping us ahead in both mature and emerging markets.
Our aim to simplify and reorganize our diabetes and cardiovascular markets takes into account the growing importance of Emerging Markets, where our Q3 results saw an impressive 10% rise in the third quarter and 8% for the first nine months. As in prior quarters, China remained a particular highlight with strong growth in both pharmaceuticals and vaccines.
Growing non-U.S. sales in the Global Diabetes market plus a rise in Praluent® sales contributed to a strong Q3 performance.
Propelling growth at Sanofi also means keeping all hands on the throttle to sustain innovation in R&D. Here’s what we have coming up:
- Dupixent® won FDA approval in the US for moderate-to-severe asthma AND it was submitted to the FDA for treatment of atopic dermatitis in adolescents;
- Libtayo was approved by FDA for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation, the first and only drug to be approved in the US in this potentially life-threatening form of skin cancer;
- Cablivi was approved in Europe for the treatment of the rare clotting disorder acquired TTP; and
- Praluent® ODYSSEY OUTCOMES results was accepted for FDA review.